Astellas Pharma Inc.
Other OTCTotal Valuation
Astellas Pharma Inc. carries a market capitalization of 24.01B, placing it among publicly traded companies globally. Its enterprise value stands at 3.49T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 24.01B |
| Enterprise Value | 3.49T |
Share Statistics
Astellas Pharma Inc. currently has 1.79B shares outstanding.
| Shares Outstanding | 1.79B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Astellas Pharma Inc. trades at a trailing price-to-earnings ratio of 37,269.26. The price-to-sales ratio is 3.46, and the price-to-book ratio stands at 3.14.
| PE Ratio | 37,269.26 |
| PS Ratio | 3.46 |
| PB Ratio | 3.14 |
| P/TBV Ratio | -15.13 |
| P/FCF Ratio | 18.79 |
| P/OCF Ratio | 24.26 |
Enterprise Valuation
On an enterprise value basis, Astellas Pharma Inc. trades at an EV/EBITDA multiple of 312.26 and an EV/FCF ratio of 22.01. The EV/Sales ratio of 4.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 312.26 provides insight into valuation relative to core operating earnings.
| EV / Sales | 4.17 |
| EV / EBITDA | 312.26 |
| EV / EBIT | 312.26 |
| EV / FCF | 22.01 |
Financial Position
Astellas Pharma Inc. maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.63, indicating elevated leverage, while an interest coverage ratio of -3.85 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.10 |
| Quick Ratio | 0.30 |
| Debt / Equity | 60.63 |
| Debt / EBITDA | -34.31 |
| Interest Coverage | -3.85 |
Financial Efficiency
| Return on Equity (ROE) | -1.97 |
| Return on Assets (ROA) | -0.54 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 0.61 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.63 |
Taxes
Over the trailing twelve months, Astellas Pharma Inc. has paid -12.58B in income taxes, reflecting an effective tax rate of 16.17.
| Income Tax | -12.58B |
| Effective Tax Rate | 16.17 |
Stock Price Statistics
Astellas Pharma Inc.'s stock has gained approximately 34.94461% over the past 52 weeks. The 50-day moving average sits at 15.16, while the 200-day moving average is 13.46.
| Beta (5Y) | N/A |
| 52-Week Price Change | 34.94461% |
| 50-Day Moving Average | 15.16 |
| 200-Day Moving Average | 13.46 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Astellas Pharma Inc. generated 836.53B in revenue and converted that into -18.76B in net income, yielding earnings per share of -10.43. EBITDA reached -27.03B, while operating income came in at -27.03B.
| Revenue | 836.53B |
| Gross Profit | 687.41B |
| Operating Income | -27.03B |
| Pretax Income | -31.35B |
| Net Income | -18.76B |
| EBITDA | -27.03B |
| EBIT | -27.03B |
| Earnings Per Share (EPS) | -10.43 |
Balance Sheet
Astellas Pharma Inc. holds 329.26B in cash and equivalents against 927.50B in total debt, resulting in a net debt position of 634.50B. Total book value stands at 920.62B, with working capital of 109.65B providing operational flexibility.
| Cash & Cash Equivalents | 329.26B |
| Total Debt | 927.50B |
| Net Debt | 634.50B |
| Equity (Book Value) | 920.62B |
| Book Value Per Share | 513.66 |
| Working Capital | 109.65B |
Cash Flow
Astellas Pharma Inc. produced 119.25B in operating cash flow over the past twelve months. After subtracting -35.19B in capital expenditures, free cash flow totaled 84.06B - equivalent to 46.90 per share.
| Operating Cash Flow | 119.25B |
| Capital Expenditures | -35.19B |
| Free Cash Flow | 84.06B |
| FCF Per Share | 46.90 |
Margins
Astellas Pharma Inc. operates with a gross margin of 82.17, reflecting its pricing power and cost economics. The operating margin of -3.23 and net profit margin of -2.24 provide insight into operational efficiency.
| Gross Margin | 82.17 |
| Operating Margin | -3.23 |
| Pretax Margin | -3.75 |
| Profit Margin | -2.24 |
| EBITDA Margin | -3.23 |
Dividends & Yields
The company's payout ratio of -334.42 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 35.01 |
| Dividend Yield | N/A |
| Payout Ratio | -334.42 |
| Shareholder Yield | 1.94 |
| FCF Yield | 5.32 |
Stock Splits
Astellas Pharma Inc.'s most recent stock split took place on April 2, 2014 with a 4:5 split ratio.
| Last Split Date | 4/2/2014 |
| Split Ratio | 4:5 |
Scores
Astellas Pharma Inc. posts an Altman Z-Score of 2.06, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.06 |